Bringing a single drug to market can take more than a decade and cost billions of dollars, with fewer than one in ten candidates successfully reaching approval. Against this backdrop, generative AI is ...
The process of discovering new drugs and bringing them to market is notoriously slow and inefficient. Amazon Web Services is ...
AWS's new AI platform grants researchers direct access to a broad library of biological foundation models for lab-in-the-loop drug discovery.
A Luxembourg-based start-up has raised $10 million to help the pharmaceutical sector exploit the power of AI to drive faster ...
Technical Report No. 56 (Revised 2026) outlines a GMP--compliant, phase--appropriate quality management system (QMS) spanning preclinical development through clinical phases and commercial readiness ...
In my previous article, I discussed how AI is rapidly transforming the drug discovery process, significantly accelerating timelines and reducing costs. However, while AI's potential in this domain is ...
Opinions expressed by Digital Journal contributors are their own. Bringing a new biologic drug from concept to clinic is a complex journey fraught with technical and regulatory hurdles. For ...
In the last few years, multispecific antibodies, such as bispecific, trispecific, and tetraspecific antibodies, have become the breakthrough stars in antibody therapeutics. Compared with conventional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results